Hepalink (Hong Kong) Limited announced that it will receive $20 million in an equity round of funding from returning investor Shenzhen Hepalink Pharmaceutical Co., Ltd. on January 23, 2016. Post transaction, the investor will maintain its stake at 100% in the company. The transaction was approved at the 19th meeting of the 3rd directorate and 14th meeting of the 3rd supervisory board of the investor.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.72 CNY | +0.58% |
|
-0.34% | -25.66% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.66% | 1.59B | |
+21.37% | 43.7B | |
+29.65% | 23.11B | |
+19.35% | 14.31B | |
+56.46% | 12.87B | |
-0.05% | 6.79B | |
-11.27% | 6.45B | |
-8.87% | 5.73B | |
+12.21% | 5.55B | |
+9.49% | 4.81B |
- Stock Market
- Equities
- 002399 Stock
- News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Hepalink (Hong Kong) Limited announced that it expects to receive $20 million in funding from Shenzhen Hepalink Pharmaceutical Co., Ltd..